Bioxyne Limited · ASX:BXN
Bioxyne — Shareholder Meeting (November 2012)
19 slides from Bioxyne's shareholder meeting presentation, Nov 29, 2012
Slide 1: AGM Presentation
For personal use only AGM Presentation 2.30pm.,November 29th 2012 33 Erskine St, Sydney. 1
Slide 2: Disclaimer
Disclaimer For personal use only This presentation is given: • for the sole purpose of providing the recipients with background information about Bioxyne’s business. • Does not constitute an offer, invitation or recommendation to subscribe for or purchase any security in Bioxyne and does not form th
Slide 3: Agenda
Agenda For personal use only " Chairman’s address " Managing Director Review " Shareholder Resolutions 3
Slide 4: Process
Process For personal use only 1. Motions will be called by the Chair – a seconder will then be called • A mover or seconder can’t move an amendment • Motion fails if it does not pose a matter for decision 2. Motion discussed (Q from floor and A by mover/ seconder) • Time limit for speaking on a moti
Slide 5: Process-II
Process-II For personal use only A scrutineer has been appointed - instruments appointing representatives are available for inspection The attendance register is available for signature Notice of Meeting – mailed to members and, absent objection, will be taken as having been read Quorum is two membe
Slide 6: Managing Director's Presentation
For personal use only Managing Director’s Presentation 6
Slide 7: Summary
Summary For personal use only " A year of transition " ASX Listed - April 2012 " Clinical Study Results June 2012 " Heads of Agreement with Vaxine Pty Ltd " Restructured Board of Directors " Shareholders to vote on future direction 7
Slide 8: Options available to the Company in June
Options available to the Company in June For personal use only " The Board assessed the following options " Development of the probiotics business " Sales of HI 164 as an OTC product " Merging with an alternative technology " Further study into HI 164 in selected patients " Market opportunity assess
Slide 9: Market Assessment
Market Assessment For personal use only " Conducted by Torreya Partners (US based) " 15 potential partners identified " Opportunity to engage with clear datasets/indications " Supported a further study " Torreya Partners engagement is now complete 9
Slide 10: Proposed Study Partners-Vaxine Pty Ltd
Proposed Study Partners-Vaxine Pty Ltd For personal use only " Internationally recognised experts in vaccine development " Experienced with large studies " First company in the world to undertake Swine flu vaccine study " Proven entrepreneurial approach to product development " Commercial and resear
Slide 11: Proposed Study Design
Proposed Study Design For personal use only " Based on analyses of Studies 002/4/5 " HI-H002 and HI-H004 indicated potential benefits of HI 164 in patients producing “copious amounts of sputum” " Study HI-H005 demonstrated reduced number of patients with copious sputum production compared to previou
Slide 12: Potential benefits in targeted group
Potential benefits in targeted group For personal use only 1.0 1.0 proportion not having an event proportion not having an event 0.8 0.8 0.6 0.6 0.4 0.4 0.2 0.2 0.0 0.0 0 1 2 3 4 5 6 7 0 1 2 3 4 5 6 7 months on study months on study 1.0 1.0 proportion not having an event proportion not having an eve
Slide 13: Study Criteria-What changes ?
Study Criteria-What changes ? For personal use only " Targeted/Defined patient group " Study matches feedback from a “Big Pharma” requirement " Focused study with local professional management " Mitigation of seasonal risk " Parallel mode of action studies 13
Slide 14: Study Funding
Study Funding For personal use only " Value of study $3.4m " Achieved through " Sale of equity " Sale of Probiotics business " Secured Convertible Note " Risk-Reward " 10% of gross revenues received upon commercialization 14
Slide 15: Further business opportunities
Further business opportunities For personal use only " Objectives " Build a portfolio of complementary assets in BXN " May include devices or pharma products " Several opportunities identified " Timeframes " In parallel with Study HI-H007 " Targeted build out by mid 2014 15
Slide 16: Proposed Road Map Forward
Proposed Road Map Forward For personal use only Commercializa)on HI 164-‐Pending results of HI-‐H007 Comple)on of clinical study. Target Q4 2014 Assessment of alternate technologies that add shareholder value Targeted Commencement of Clinical Study pending shareholder approval 16
Slide 17: Targeted Company Portfolio-2014
Targeted Company Portfolio-2014 For personal use only Asset Phase 1 Phase 2 Phase 3 Comments HI 164 Pending shareholder approval to proceed with further study. Asset 1 Ideally a device/ product that can be commercialised short term. Asset 2 Asset 3 17
Slide 18: EGM
EGM For personal use only " Shareholders to vote on the future direction of the Company " Either " HI 164 study with a supporting capital raise, or " A future with other technologies " EGM targeted for late 2012/early 2013 18
Slide 19: For personal use only
For personal use only 19